Discussion This study demonstrated that NSCLC patients with prior CIP had comparable transition rates to second-line therapy but showed a trend toward shorter OS and experienced a higher incidence of drug-induced pneumonitis with DTX-based regimens.
← all excerpts
Analysis of second-line therapy in patients with prior pneumonitis receiving first-line combination immunotherapy for advanced non-small cell lung cancer.
1
—
—